Molbio Diagnostics IPO GMP today is Rs 220. Investors can use this GMP along with price band and subscription status for a better IPO review.
Upcoming
Mainboard IPO
MOLBIO
Molbio Diagnostics
Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases. The company’s core business revolves around its proprietary ‘Truenat’ platform, a portable, battery-operated polymerase chain reaction (PCR) system designed for use in resource-limited settings. This platform provides rapid and accurate test results within approximately one hour. The company’s primary source of revenue is the sale of its ‘Truenat’ devices and the recurring sale of compatible, disease-specific micro-PCR test kits. Molbio offers a wide range of tests for various infectious diseases, including tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. Through its subsidiaries, the company also provides devices related to radiology and digital pathology.
IPO Details
Complete IPO information
| Current GMP | ₹220 |
|---|---|
| Estimated Listing Gain | +27.26% |
| Price Band | ₹768.00 - ₹807.00 |
| Issue Price | ₹807.00 |
| Listing Price | TBA |
| Lot Size | 18 Shares |
| Issue Type | Mainboard |
| Issue Size | Approx ₹939.70 Cr |
| Registrar | TBA |
| Exchange | BSE, NSE |
| Retail Quota | TBA |
| Overall Subscription | TBA |
| Listing Date | 17 Aug 2026 |
| Minimum Investment | ₹14,526 |
Timeline
IPO roadmap at a glance
01
Bidding Opens
10 Aug 2026
02
Bidding Closes
12 Aug 2026
03
Allotment
13 Aug 2026
04
Listing
17 Aug 2026
Grey Market Premium
Daily GMP status
| Date | GMP | Change | Gain |
|---|---|---|---|
| 6 August | ₹170 | - | 21.06% |
Market Lot
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 Lot | 18 | ₹14,526 |
| Retail Maximum | 13 Lot | 234 | ₹1,88,838 |
| S-HNI Minimum | 14 Lot | 252 | ₹2,03,364 |
| S-HNI Maximum | 68 Lot | 1,224 | ₹9,87,768 |
| B-HNI Minimum | 69 Lot | 1,242 | ₹10,02,294 |
Issue Notes
Important takeaways before applying
Strengths
- Proprietary TruNAT platform enables rapid, point-of-care molecular diagnostics.
- Strong footprint in government and public health procurement programs.
- Wide disease coverage including TB, COVID-19, HIV, hepatitis and HPV.
- In-house R&D supported by integrated manufacturing capabilities.
- Global presence with products deployed across multiple countries.
Risks
- Heavy dependence on government and international aid agency funding.
- High revenue concentration from tuberculosis-related test kits.
- A limited number of large customers contribute a significant share of revenues.
- Regulatory delays may impact the commercialisation of new diagnostic tests.
- Demand fluctuations are linked to public health policies and funding cycles.
Analysis
Molbio Diagnostics IPO Details
Molbio Diagnostics Limited is launching its Initial Public Offering (IPO) through the Book Built Issue route. The IPO consists of a combination of a Fresh Issue of equity shares and an Offer for Sale (OFS) by existing shareholders. The proceeds from the fresh issue are expected to support the company's expansion, research and development initiatives, manufacturing capabilities, and general corporate purposes, while the OFS enables existing shareholders to partially monetize their investment. :contentReference[oaicite:0]{index=0}
The equity shares of Molbio Diagnostics Limited are proposed to be listed on both the BSE and NSE. Investors can subscribe to the IPO during the issue period at the announced price band. :contentReference[oaicite:1]{index=1}
| Particular | Details |
|---|---|
| IPO Open Date | August 10, 2026 |
| IPO Close Date | August 12, 2026 |
| Face Value | ₹1 Per Equity Share |
| IPO Price Band | ₹768 to ₹807 Per Share |
| Issue Size | Approx ₹939.70 Crores |
| Fresh Issue | Approx ₹200 Crores |
| Offer for Sale (OFS) | Approx 91,66,000 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
Analysis
Molbio Diagnostics IPO Reservation
The Molbio Diagnostics IPO follows the SEBI-prescribed reservation structure for a Book Built Issue. The public issue is allocated among Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), Retail Individual Investors (RIIs), and Anchor Investors. The final allotment in each category will depend on investor participation and the basis of allotment finalized after the IPO closes.
The category-wise reservation details for the public issue are provided below.
| Investor Category | Shares Offered | Reservation (%) |
|---|---|---|
| Anchor Investor | – Shares | -% |
| Qualified Institutional Buyers (QIB) (Excluding Anchor) | – Shares | 50% |
| Non-Institutional Investors (NII) | – Shares | 15% |
| Retail Individual Investors (RII) | – Shares | 35% |
Note: The exact number of shares reserved for each investor category, including Anchor Investors, will be announced before the IPO opens for subscription. The final allocation will be completed in accordance with SEBI regulations and the approved issue structure.
Analysis
Molbio Diagnostics IPO Anchor Investors
Molbio Diagnostics Limited has reserved a portion of its IPO for eligible Anchor Investors before the public issue opens for subscription. Anchor investors are Qualified Institutional Buyers (QIBs) who participate in the IPO one working day before the public issue, helping improve price discovery and strengthen market confidence in the offering.
The details below include the anchor bidding schedule, proposed allocation, issue size, and the applicable SEBI-prescribed lock-in periods. The final list of anchor investors and allocation details will be announced after the completion of the anchor placement process.
| Particular | Details |
|---|---|
| Anchor Bidding Date | August 7, 2026 |
| Anchor Investors List | To be announced |
| Shares Offered | [.] Shares |
| Anchor Issue Size | [.] Crores |
| Lock-in Period End Date (50% Shares – 30 Days) | 2026 |
| Lock-in Period End Date (Remaining 50% Shares – 90 Days) | 2026 |
Note: The final anchor investor list, number of shares allotted, anchor issue size, and exact lock-in period end dates will be updated after the completion of the anchor allocation process. The lock-in period for anchor investors will be applicable in accordance with SEBI regulations.
Analysis
Molbio Diagnostics IPO Dates
The Molbio Diagnostics IPO will open for subscription on August 10, 2026 and close on August 12, 2026. The basis of allotment is expected to be finalized on August 13, 2026. Refunds for unsuccessful applicants and the credit of allotted equity shares to successful investors' demat accounts are scheduled for August 14, 2026.
The equity shares of Molbio Diagnostics Limited are proposed to be listed on both the BSE and NSE on August 17, 2026. Investors should keep track of these important dates to monitor the IPO subscription, allotment process, and listing schedule.
| IPO Event | Date |
|---|---|
| IPO Open Date | August 10, 2026 |
| IPO Close Date | August 12, 2026 |
| Basis of Allotment | August 13, 2026 |
| Refunds | August 14, 2026 |
| Credit to Demat Account | August 14, 2026 |
| IPO Listing Date | August 17, 2026 |
Note: The above IPO schedule is tentative and may be revised by the company, the registrar, or the stock exchanges. Investors are advised to refer to the official IPO documents and exchange announcements for the latest updates regarding the issue timeline.
Analysis
Molbio Diagnostics IPO Promoters and Holding Pattern
The promoters of Molbio Diagnostics Limited have been instrumental in building the company's presence in the molecular diagnostics and medical technology sector. Following the IPO, the promoter group will continue to retain a significant ownership stake, while the public shareholding will increase through the fresh issue and Offer for Sale (OFS).
The table below presents the promoter and public shareholding pattern before and after the IPO based on the proposed issue structure.
Promoters of Molbio Diagnostics Limited
- Chandrasekhar Bhaskaran Nair
- Exxora Trading LLP
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Sriram Natarajan
| Category | Pre IPO Shares | Pre IPO Holding | Post IPO Shares | Post IPO Holding |
|---|---|---|---|---|
| Promoter and Promoter Group | 52,597,450 | 46.65% | 4,34,31,450 | 37.69% |
| Others* | 60,162,300 | 53.35% | 7,18,08,546 | 62.31% |
| Total | 11,27,59,750 | 100% | 11,52,39,996 | 100% |
Note: The post-IPO shareholding pattern is based on the proposed issue structure and may change after the final allotment of shares. The promoter group will continue to hold a substantial stake in the company following its listing on the BSE and NSE.
Analysis
Molbio Diagnostics IPO Objects of the Issue & Utilisation of Proceeds
Molbio Diagnostics Limited intends to utilize the net proceeds from its Initial Public Offering (IPO) to strengthen its research capabilities and expand its manufacturing infrastructure. A significant portion of the funds will be invested in establishing a state-of-the-art research and development facility, creating a Center of Excellence, and expanding office infrastructure to support future innovation.
The company will also utilize a portion of the proceeds to purchase plant, machinery, and other equipment for its manufacturing units in Goa and Visakhapatnam. The remaining funds, if any, will be utilized for general corporate purposes in accordance with the objectives outlined in the offer documents.
| Purpose | Amount |
|---|---|
| Funding Capital Expenditure Towards Setting up Infrastructure for the Research & Development Facility, Center of Excellence and Connected Office Space | ₹118.08 Crores |
| Funding Capital Expenditure Towards the Purchase of Plant, Machinery and Other Equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit | ₹79.04 Crores |
| General Corporate Purposes | ₹- |
Note: The proposed utilization of IPO proceeds is based on the objectives disclosed in the Draft Red Herring Prospectus (DRHP)/Red Herring Prospectus (RHP). The company may revise the allocation of funds in accordance with business requirements, regulatory approvals, and applicable SEBI guidelines.
Analysis
Molbio Diagnostics About Ipo
To be updated soon
Analysis
Molbio Diagnostics IPO Company Financial Report
Molbio Diagnostics Limited has demonstrated strong financial performance over the last three financial years. The company has consistently increased its revenue, improved profitability, and significantly expanded its asset base, reflecting healthy business growth and increasing demand for its molecular diagnostics and healthcare solutions.
The financial summary below provides an overview of the company's revenue, expenses, Profit After Tax (PAT), and total assets for the reported financial years. These audited figures help investors evaluate Molbio Diagnostics Limited's historical financial performance before its proposed IPO listing.
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2024 | ₹840.66 Cr. | ₹657.83 Cr. | ₹83.54 Cr. | ₹1,221.06 Cr. |
| 2025 | ₹1,027.94 Cr. | ₹820.41 Cr. | ₹138.58 Cr. | ₹1,461.56 Cr. |
| 2026 | ₹1,455.17 Cr. | ₹1,221.35 Cr. | ₹164.14 Cr. | ₹2,148.42 Cr. |
Amount in ₹ Crores: The above financial figures are based on the audited financial statements disclosed by Molbio Diagnostics Limited in its IPO documents. They provide a summary of the company's historical financial performance and financial position prior to its proposed listing.
Analysis
Molbio Diagnostics IPO Valuation – FY2026
The valuation metrics of Molbio Diagnostics Limited provide investors with important insights into the company's profitability, operational efficiency, financial strength, and overall valuation before the IPO. Key indicators such as Earnings Per Share (EPS), Return on Equity (ROE), Return on Capital Employed (ROCE), EBITDA Margin, Return on Net Worth (RoNW), Debt-to-Equity Ratio, and Net Asset Value (NAV) help assess the company's financial performance and investment potential.
Based on the FY2026 audited financial statements, Molbio Diagnostics has reported healthy profitability, strong operating margins, and efficient capital utilization. The final Price-to-Earnings (P/E) ratio will be available after the IPO price is finalized and the company's equity shares are listed on the BSE and NSE.
| KPI | Values |
|---|---|
| ROE | 15.59% |
| ROCE | 17.55% |
| EBITDA Margin | 22.56% |
| PAT Margin | 11.28% |
| Debt to Equity Ratio | [.] |
| Earning Per Share (EPS) | ₹14.77 (Basic) |
| Price / Earnings (P/E) Ratio | N/A |
| Return on Net Worth (RoNW) | 14.55% |
| Net Asset Value (NAV) | ₹101.51 |
Note: The above valuation metrics are based on the FY2026 audited financial statements of Molbio Diagnostics Limited. The Debt-to-Equity Ratio will be updated once disclosed in the final offer documents. The final Price-to-Earnings (P/E) ratio will be calculated after the IPO price is finalized and the company's equity shares are listed on the BSE and NSE.
Analysis
Molbio Diagnostics IPO Peer Group Comparison
Molbio Diagnostics Limited operates in the diagnostics and medical technology sector. Comparing the company with established listed healthcare and diagnostics businesses helps investors assess its profitability, valuation, operational efficiency, and competitive position within the industry.
The table below compares important financial metrics such as Earnings Per Share (EPS), Price-to-Earnings (P/E) Ratio, Return on Net Worth (RoNW), Net Asset Value (NAV), and annual income of comparable listed companies.
| Company | EPS | P/E Ratio | RoNW (%) | NAV (₹) | Income |
|---|---|---|---|---|---|
| Poly Medicure Limited | 31.79 | 52.61 | 10.37% | 306.45 | ₹1,875.26 Cr. |
| Dr. Lal PathLabs Limited | 30.24 | 62.20 | 20.78% | 145.00 | ₹2,762.91 Cr. |
| Metropolis Healthcare Limited | 9.19 | 63.72 | 12.56% | 72.98 | ₹1,645.85 Cr. |
| Vijaya Diagnostics Centre Limited | 16.81 | 81.02 | 18.07% | 93.02 | ₹814.20 Cr. |
Note: The peer group comparison is based on publicly available financial information disclosed in the IPO offer documents. Investors should evaluate these metrics together with Molbio Diagnostics Limited's financial performance, valuation, business model, and future growth prospects before making an investment decision.
Analysis
IPO Lead Managers aka Merchant Bankers
- Kotak Mahindra Capital Co. Ltd.
- IIFL Capital Services Ltd.
- Jefferies India Pvt. Ltd.
- Motilal Oswal Investment Advisors Ltd.
FAQ
Molbio Diagnostics IPO FAQs
Molbio Diagnostics IPO price band is Rs 768.00 to Rs 807.00. Check the latest issue price, lot size and GMP together before applying.
Molbio Diagnostics IPO open date is 10 Aug 2026, close date is 12 Aug 2026, and listing date is 17 Aug 2026.
Molbio Diagnostics IPO lot size is 18 shares. The minimum retail investment is Rs 14,526.
Molbio Diagnostics is classified as a Mainboard IPO. This helps investors quickly understand the issue category and exchange segment.
Molbio Diagnostics IPO subscription status currently shows Subscription data is currently awaited.
Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases. The company’s core business revolves around its proprietary ‘Truenat’ platform, a portable, battery-operated polymerase chain reaction (PCR) system designed for use in resource-limited settings. This platform provides rapid and accurate test results within approximately one hour. The company’s primary source of revenue is the sale of its ‘Truenat’ devices and the recurring sale of compatible, disease-specific micro-PCR test kits. Molbio offers a wide range of tests for various infectious diseases, including tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. Through its subsidiaries, the company also provides devices related to radiology and digital pathology.
Molbio Diagnostics IPO issue size is 939.70 and the expected allotment date is 13 Aug 2026.